Corporate - Media & Press - Press Release
Arrayit Corporation Announces Nationwide Allergy Testing Sales and Distribution Network
GlobeNewswire June 18, 2018 5:30 AM EST Source: Arrayit Corporation
Sunnyvale, June 18, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation Announces Nationwide Allergy Testing Sales and Distribution Network
June 18, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that the company has engaged a nationwide network of professional sales representatives (“sales reps”) to sell and distribute the company’s allergy tests across the Continental United States, with focus areas in the Pacific Northwest, West, Southwest, Rocky Mountain, Midwest, Northeast and Southeast regions. The network comprises 1,700 sales professionals including 500 sales reps with specific training in finger stick sampling, blood card collection and microarray technology. This extensive professional network will be used to enroll hospitals, health maintenance organizations (HMOs), doctor’s and dentist’s offices, health clinics and retail stores into the allergy-testing program.
Arrayit allergy tests utilize non-invasive and convenient finger stick sampling and blood card collection, in conjunction with patented and proprietary protein microarray technology, to rapidly and accurately measure immunoglobulin E (IgE) antibodies in the human bloodstream produced by exposure to 120 common food and environmental allergens. Personalized allergy testing assists health care professionals to more easily identify, treat and prevent allergy and asthma by combining molecular testing with a patient’s medical history, symptomology and a physician’s diagnosis. Arrayit allergy tests are manufactured and processed in the company’s Clinical Laboratory Improvement Amendments (CLIA) laboratory licensed by the State of California and the Centers for Medicare and Medicaid Services (CMS), and benchmarked by the leading laboratory proficiency testing organization, the College of American Pathologists (CAP).
Arrayit CEO Rene Schena states, “We perceive significant synergies between our highly automated allergy testing technology and our newly-contracted network of medical sales professionals working on our behalf to promote allergy testing nationally to patients covered by private and public health insurance. Arrayit finger stick allergy tests are particularly beneficial to pediatric patients, special needs children, seniors, and immunotherapy patients requiring testing at frequent intervals.”
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the research, biotechnology, pharmaceutical, clinical and healthcare sectors through the discovery, development and manufacture of proprietary life science and personalized medicine products and services to advance biomedical research and improve wellness and human health. Please visit www.arrayit.com for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's public filings.
Copyright 1993-2018 Arrayit Corporation. All rights reserved.